Kyowa Kirin Taiwan Co., Ltd.

Poteligeo® launched in Europe for the treatment for mycosis fungoides (MF) and Sézary syndrome (SS).

Crysvita® approved in the US for the treatment of tumor-induced osteomalacia (TIO).

New Vision toward 2030 designed to realize the creation and delivery of life-changing value.

Agreement reached with Amgen to jointly develop and commercialize KHK4083, a Kyowa Kirin-discovered anti-OX40 fully human monoclonal antibody.

Declared support for the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD).

Global DE&I Statement adopted with 40% of global leaders to be female by 2030.

An automated injection device "G-Lasta® Subcutaneous Injection 3.6 mg BodyPod" launched in Japan for the long-acting G-CSF preparation, G-Lasta®.

Q-TOWER, the new biopharmaceutical analysis facility completed at Takasaki Plant, Kyowa Kirin's major biopharmaceutical manufacturing site.

PHOZEVEL® approved in Japan for the treatment of Hyperphosphatemia in chronic kidney disease patients.

Kyowa Kirin announced the acquisition of UK company Orchard Therapeutics with strength in hematopoietic stem cell gene therapy.

Lenmeldy™ , an innovative hematopoietic stem cell (HSC) gene therapy, approved and launched in the United States.

A new biologics manufacturing plant decided to be established in North Carolina, the United States.

A global strategic collaboration signed to develop and commercialize menin inhibitor ziftomenib in acute leukemias with Kura Oncology.

Completion of the HB7 Building, a new biopharmaceutical DS (Drug Substance) manufacturing facility at the Takasaki Plant, to strengthen global manufacturing capacity and talent development.

FDA approval and U.S. launch of KOMZIFTI™ (ziftomenib) for adult AML (Acute Myeloid Leukemia).